

## Who Manufactures Sinovac Vaccine



(Picture source: Sohu)

The vaccines to coronavirus(COVID19, CCP virus) Chinese Communist party(CCP) promoted globally and suppressed Chinese including Hong Kongers to take included Sinovac vaccine. Then why did this happen? It's similar to the pattern CCP promoted Huawei 5G through coercion diplomacy.

### **Overall background of Sinovac**

As reported by Business Wire on 06 December 2020, Sinovac Life Sciences Co., Ltd. (“Sinovac LS”) (formerly known as Sinovac Research and Development Co., Ltd.), shown on the package picture above as the manufacturer of Sinovac vaccine, is a subsidiary of Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA).<sup>1</sup> The relationship could be verified on page F-12 of the F-20 document filed with US SEC (annual report) on 30 April 2020 as follows.

| Name   | Date of incorporation or establishment | Place of incorporation (or establishment) /operation | Percentage of ownership as of December 31, 2019 | Percentage of ownership as of December 31, 2018 | Principal activities   |
|--|--|--|---|---|--|
| Sinovac Biotech (Hong Kong) Limited ("Sinovac Hong Kong")        | October 2008                           | Hong Kong  | 100%  | 100%  | International sales and marketing                                  |
| Sinovac Biotech Co., Ltd. ("Sinovac Beijing")                    | April 2001                             | People's Republic of China ("PRC")                   | 73.09%  | 73.09%  | Research and development, production and sales of vaccine products |
| Sinovac Research & Development Co., Ltd. ("Sinovac R&D")         | May 2009                               | PRC  | 100%  | 100%  | Research and development of vaccine products                       |
| Sinovac (Dalian) Vaccine Technology Co., Ltd. ("Sinovac Dalian") | January 2010                           | PRC  | 67.86%  | 67.86%  | Research and development, production and sales of vaccine products |
| Sinovac Biomed Co., Ltd.   | April 2015                             | PRC  | 100%  | 100%  | Distribution of vaccine products                                   |

The company's website informs that Sinovac shares are listed on the NASDAQ Global Select Market with symbol of SVA and the overall group's main products are products to viruses. It also confirms Sinovac owns Sinovac Biotech Co., LTD, Sinovac (Dalian) Vaccine Technology Co., Ltd., Sinovac LS and Sinovac Biomed Co.,LTD, translated with Chrome Browser from Chinese respectively as Beijing Kexin Biological Products Co., Ltd., Kexing (Dalian) Vaccine Technology Co., Ltd., Beijing Kexing Zhongwei Biotechnology Co., Ltd. and Beijing Kexing Zhongyi Biomedicine, through its wholly-owned subsidiary Sinovac Biotech (Hong Kong) Co., Ltd, translated with Chrome Browser as Kexing Holdings (Hong Kong) Co., Ltd.

The webpage was translated by Google Chrome from Chinese into English as follows:

English translation version:

**SINOVAC 科兴**

Back to homepage    Add to Favorites

Simplified Chinese    English

请输入关键字    搜索

about Us    products and services    R&D and innovation    News Center    Career Development    Investor Relations

为人类消除疾病提供疫苗

about Us

Current Location: Home > about Us > Company Overview

> Company Overview

- development path
- Cultural concept
- Social responsibility
- Honor

Kexing Holding Biotechnology Co., Ltd. is a high-tech biotechnology company headquartered in Beijing. It is currently listed on the Nasdaq Global Select Market (NasdaqGS: SVA). The company owns Beijing Kexin Biological Products Co., Ltd., Kexing (Dalian) Vaccine Technology Co., Ltd., Beijing Kexing Zhongwei Biotechnology Co., Ltd. and Beijing Kexing Zhongyi Biomedicine through its wholly-owned subsidiary Kexing Holdings (Hong Kong) Co., Ltd. The four companies of the Co., Ltd., with the mission of "providing vaccines for humans to eliminate diseases", are committed to the research, development, production and sales of human vaccines and related products, and provide services for disease prevention and control.

At present, the company's listed products mainly include: a new class 1 preventive biological product-Enterovirus 71 inactivated vaccine (Yierlaifu®), China's first inactivated hepatitis A vaccine (Haierlaifu) that has passed the WHO pre-certification ®), trivalent influenza virus split vaccine (Anerlif®), quadrivalent influenza virus split vaccine, live attenuated varicella vaccine, hepatitis A and B combined vaccine (Belleflex®) and live attenuated mumps Vaccines, etc.

In addition, the company has successively developed the world's first SARS coronavirus inactivated vaccine (complete phase I clinical study), China's first pandemic influenza (H5N1) vaccine (Panerlaifu®) and the world's first type A vaccine The H1N1 influenza vaccine (Panerlaifu.1®) has contributed to disease prevention and control in China and even the world.

Since its establishment, the company has independently developed 7 China's first vaccine products and the world's first vaccine products, and obtained 5 national new drug certificates, including 2 first-class new drug certificates; 2 second-class national science and technology progress awards and 4 Beijing science and technology progress awards; Undertook 47 national and provincial science and technology projects; obtained nearly 60 national invention patents for core technologies, and published more than 120 SCI papers on research results, many of which were published in New England Journal of Medicine, The Lancet, and Science, Nature and other top international academic journals.

The company is developing a series of new products, including Sabin strain inactivated polio vaccine, 23-valent pneumococcal polysaccharide vaccine, novel coronavirus inactivated vaccine and multiple combination vaccines.

The company mainly sells vaccines in China and is also looking for growth opportunities in the international market. The company's products are registered in more than 30 countries outside of China.

(Note:Kexin, Chinese pronunciation of“科兴”, is Sinovac; Beijing Kexing Zhongwei Biotechnology Co., Ltd. )

Original Chinese language version

**SINO VAC 科兴** [返回首页](#) [加入收藏](#) [简体中文](#) | [English](#)

请输入关键字  [搜索](#)

[关于我们](#) [产品与服务](#) [研发与创新](#) [新闻中心](#) [职业发展](#) [投资者关系](#) [联系我们](#)

## 为人类消除疾病提供疫苗

当前位置: [首页](#) > [关于我们](#) > [公司概况](#)

**公司概况**

- 发展历程
- 文化理念
- 社会责任

科兴控股生物技术有限公司是一家总部位于北京的生物高新技术企业，目前在纳斯达克全球精选市场（ NasdaqGS : SVA ）上市。公司通过全资子公司科兴控股（香港）有限公司拥有北京科兴生物制品有限公司、科兴（大连）疫苗技术有限公司、北京科兴中维生物技术有限公司和北京科兴中益生物医药有限公司四家企业，以“为人类消除疾病提供疫苗”为使命，致力于人用疫苗及其相关产品的研究开发、生产和销售，为疾病预防控制提供服务。

目前公司上市产品主要包括：预防用生物制品1类新药——肠道病毒71型灭活疫苗（益尔来福®），中国第一支通过WHO预认证的甲肝灭活疫苗（孩尔来福®），三价流感病毒裂解疫苗（安尔来福®），四价流感病毒裂解疫苗，水痘减毒活疫苗，甲型乙型肝炎联合疫苗（倍尔来福®）以及腮腺炎减毒活疫苗等。

此外公司还曾先后研制出全球第一支SARS冠状病毒灭活疫苗（完成I期临床研究）、中国第一支大流行流感（H5N1）疫苗（盼尔来福®）以及全球第一支甲型H1N1流感疫苗（盼尔来福.1®），为中国乃至全球疾病预防控制做出了贡献。

公司成立至今，自主研发出7个中国首创和全球首创疫苗产品，获得国家新药证书5件，其中一类新药证书2件；获得国家科技进步二等奖2项，北京市科技进步奖4项；承担国家级和省部级科技项目47项；核心技术获得国家发明专利近60项，研究成果发表SCI论文120余篇，其中多篇发表在《新英格兰医学杂志》、《柳叶刀》、《科学》、《自然》等国际顶级学术刊物上。

公司正在开发一系列新产品，包括Sabin株脊髓灰质炎灭活疫苗、23价肺炎球菌多糖疫苗、新型冠状病毒灭活疫苗及多个联合疫苗等。

(Picture source: Official webpage of Sinovac<sup>2</sup>)

According to webpage Beijing Enterprise Credit Information website of CCP government, Sinovac LS was incorporated on 7 May 2009 in the same address as shown on the package above with submitted capital \$40,51m. Keding Investment (Hong Kong) Limited (Keding Hong Kong), Prime Success,L.P., Talent Forward Limited, Theresa Tse, VIVO CAPITAL FUND IX, L.P. and Sinovac Hong Kong had submitted capital for \$5.14m, \$2.57m, \$6.09m, \$0.14m, \$2.57m and \$24m in the Sinovac LS. But prior to the capital increase as at 4 December 2020, its shareholders only included Sinovac Hong Kong and Keding Hong Kong. Therefore Sinovac LS is a foreign-owned company with registration number 91110108688350614B active, the major shareholders of which are registered in Hong Kong still regarded as overseas by CCP government in Mainland China (PRC) despite its long practices of violating Hong Kong autonomy and actual control over Hong Kong regime disregarding its duties in The Sino-British Joint Declaration on the Question of Hong Kong signed on 19 December 1984 by Zhao Ziyang and Margaret Thatcher and registered with United Nations with Registration Number 23391. Shareholders of Sinovac LS take the form of natural person, limited corporation and limited partnership, as show below.



## 北京科兴中维生物技术有限公司

存续 (在营、开业、在册)

统一社会信用代码: 91110108688350614B

法定代表人: 尹卫东

注册资本: 4051 万

成立日期: 2009-05-07

住所: 北京市大兴区中关村科技园大兴生物医药产业基地天富街21号1号楼

### 股东及出资信息

| 序号 | 股东名称                              | 股东类型     | 证照/证件类型      | 证照/证件号码 |
|----|-----------------------------------|----------|--------------|---------|
| 1  | 科鼎投资 (香港) 有限公司                    | 外国(地区)企业 |              | 2986122 |
| 2  | 永恩国际有限合伙企业 (Prime Success,L.P.)   | 外国(地区)企业 |              | 90280   |
| 3  | 香港俊领有限公司 (Talent Forward Limited) |          |              | 1199173 |
| 4  | 谢其润                               |          |              |         |
| 5  | 科兴控股 (香港) 有限公司                    | 外国(地区)企业 | 企业法人营业执照(公司) | 1281167 |

| 序号 | 股东名称   | 股东类型     | 证照/证件类型 | 证照/证件号码 | 详情                 |
|----|--|----------|---------|---------|--------------------|
| 1  | 维梧资本第九期基金有限合伙企业 (VIVO CAPITAL FUND IX, L.P.) | 外国(地区)企业 |         | 6794077 | <a href="#">查看</a> |

| 变更事项          | 变更前内容   | 变更后内容   | 变更日期       |
|---------------|---|---|------------|
| 董事 (理事)、经理、监事 | 高强,<br>王敬宁,<br>尹卫东*                                 | 高强,<br>金东华,<br>梅萌,<br>王敬宁,<br>王楠,<br>尹卫东*   | 2020-12-04 |
| 投资人           | 科鼎投资 (香港) 有限公司,外国(地区)企业,<br>科兴控股 (香港) 有限公司,外国(地区)企业 | 科鼎投资 (香港) 有限公司,外国(地区)企业,<br>科兴控股 (香港) 有限公司,外国(地区)企业,<br>维梧资本第九期基金有限合伙企业 (VIVO CAPITAL FUND IX, L.P.) ,外国(地区)企业,<br>香港俊领有限公司 (Talent Forward Limited) ,,<br>谢其润,,<br>永恩国际有限合伙企业 (Prime Success,L.P.) ,外国(地区)企业 | 2020-12-04 |
| 注册资本          | 2823.53万美元  | 4051.32万美元  | 2020-12-04 |

(Picture source: Beijing Enterprise Credit Information<sup>3</sup>)

### **The Incorporation of Sinovac LS's other shareholders**

As shown at the website of SEC, Prime Success,L.P.<sup>4</sup> and VIVO CAPITAL FUND IX, L.P.<sup>5</sup> were incorporated respectively in the Cayman Islands and Delaware. VIVO CAPITAL FUND IX, L.P. together with VIVO CAPITAL IX, LLC were incorporated on 12 March 2018, just the same day. In Cayman Islands, there were also three companies-PRIME SUCCESS INVESTMENT LIMITED, PRIME SUCCESS HOLDING LIMITED and PRIME SUCCESS LTD-with names similar to Prime Success,L.P.

Keding Investment (Hong Kong) Limited and Talent Forward Limited were incorporated on 20 Oct 2020 and 31 Dec 2007 respectively.

|                        |   |
|------------------------|---|
| CR No.:                | 2986122   |
| Company Name:          | Keding Investment (Hong Kong) Limited<br>科鼎投資(香港)有限公司 |
| Company Type:          | Private company limited by shares                     |
| Date of Incorporation: | 20-OCT-2020   |

|                        |                                    |
|------------------------|------------------------------------|
| CR No.:                | 1199173                            |
| Company Name:          | Talent Forward Limited<br>香港俊領有限公司 |
| Company Type:          | Private company limited by shares  |
| Date of Incorporation: | 31-DEC-2007                        |

(Picture resource: Hong Kong e-Registry)

### **Who is Theresa Tse**

As reported by the Bloomberg on 7 December 2020, Sino Biopharmaceutical Limited (Sino Biopharm, HKEX: 1177) announced the investment of \$515m in Sinovac LS when Ms. Theresa Tse made a speech as the chairwomen of Sino Biopharm.<sup>6</sup> The annual report for the year ended with 31 December 2018 of Sino Biopharmaceutical Limited verified she was the chairman of Sino Biopharm on page 22.<sup>7</sup>

### **Sinovac Hong Kong**

Hong Kong e-Registry informed us that Sinovac Hong was incorporated on 21 Oct 2008 with English name Sinovac Biotech(Hong Kong) Limited while its Chinese name was amended once on 8 Mar 2010.

|  |  |
|--|--|
| CR No.:                                    | 1281167  |
| Company Name:                              | Sinovac Biotech (Hong Kong) Limited<br>科興控股(香港)有限公司    |
| Company Type:                              | Private company limited by shares                      |
| Date of Incorporation:                     | 21-OCT-2008  |
| Active Status:                             | Live   |
| Remarks:                                   | -  |
| Winding Up Mode:                           | -  |
| Date of Dissolution /<br>Ceasing to Exist: | -  |
| Register of Charges:                       | Unavailable  |
| Important Note:                            | -  |
| <b>Name History</b>                        |  |
| <b>Effective Date</b>                      | <b>Name Used</b>                                       |
| 08-MAR-2010                                | Sinovac Biotech (Hong Kong) Limited<br>科興控股(香港)有限公司    |
| 21-OCT-2008                                | Sinovac Biotech (Hong Kong) Limited<br>中維科生物技術(香港)有限公司 |

(Picture resource: Hong Kong e-Registry)

### **Sinovac Holdings**

Sinovac's annual report showed to us that it was incorporated in Antigua-a country with non-transparent companies information making it hard to search<sup>8</sup>-on 1 March 1999 with prior name Net-Force System Inc altered in 2003 and its consolidated financial statements were prepared on the basis of its control over Sinovac Hong Kong, Sinovac Biotech Co., Ltd, Sinovac LS, Sinovac (Dalian) Vaccine Technology Co., Ltd and Sinovac Biomed Co., Ltd.<sup>9</sup>

### **Shareholding structure of Sinovac**

Page 65 of annual report outlined that major shareholders included SAIF Partners IV L.P., SAIF IV GP, L.P., SAIF IV GP Capital Ltd, 1Globe Capital LLC, Prime Success, L.P., Green Vision Partners Limited, Advantech Capital Partners Ltd, Vivo Capital, LLC, Vivo Capital VIII, LLC, Vivo Capital IX, LLC, Weidong Yin and other management members. But there were more than 0.1 billion outstanding shares and the abovementioned shareholders didn't own more than 0.07 billion shares. It's not news that the audit work performed on financial statements of entities from People's Republic of China registered with US SEC can't be investigated by US authorities because of CCP's obstacles in terms of national security and national secrecy. Therefore, it will be a blunder to trust its annual report completely and it's uncertain whether there were other major shareholders undisclosed. Readers could search the backgrounds of shareholders of the abovementioned shareholders at the websites of Cayman Islands and Delaware respectively to find the final truths about who are the real beneficiaries of Sinovac Vaccine.

### **Who are the Sinovac's management?**

As disclosed on pages 57-58 of annual report, there were close relations among management, CCP regime and Hong Kong regime.

Weidong Yin, chairman, president, chief executive officer and secretary since September 2003, previously worked as a medical doctor in infectious disease at the Communist China Center for Disease Control and Prevention (CCP's CDC), Tangshan City, Hebei province, a principal investigator at the CCP's Ministry of Science and Technology for many key governmental R&D programs such as Inactivated Hepatitis A Vaccine R&D, Inactivated SARS Vaccine R&D and New Human Influenza Vaccine (H5N1) R&D. He was also the president of Zhongguancun Listed Companies Association, whose charter dictated "Article 4 This association adheres to the overall guidance of the Communist Party of China. According to the provisions of the Constitution of the Communist Party of China, this association does not currently have the conditions to establish a party organization alone. It conducts party work through the establishment of a joint party organization and invites the responsible person of the party organization to participate Management meeting of the Association. Hear the opinions of party organizations on important decisions, important business activities, large expenditures, receiving large donations, and carrying out foreign-related activities... The leading agency for party building is the Comprehensive Committee of the Chamber of Commerce of the Beijing Municipal Industry Association of the Communist Party of China" as translated with Google Chrome Translate.<sup>10</sup>

Yuk Lam Lo, an independent director since March 2006, was the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau HKSAR and heavily involved in several committees of the CCP Hong Kong regime. He had been appointed as Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund, HKSAR. In PRC, He was a Member of Chinese People's Political Consultative Conference in Jilin province, and a Consultant of the CCP's CDC. He had been an Independent Director of CSPC Pharmaceutical Group Limited (1093.HK), Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hangsen Investment Management Limited. As informed by website of Hangsen Bank, Hangsen Investment Management Limited, established in 1993, was once the largest provider of exchange-traded funds (ETF) in Hong Kong in terms of average daily turnover, among the first group of northbound Mainland-Hong Kong Mutual Recognition of Funds-funding securities traded in PRC-managers and the first group of Qualified Foreign Institutional Investor Scheme fund-funding investments in PRC-managers in Hong Kong. The Company launched Hong Kong's first Renminbi Qualified Foreign Institutional Investor Scheme ETF from a local financial institution, Hong Kong's first retail index fund and the world's first renminbi denominated gold ETF. The photo of 25 anniversary also evidenced that the fund was heavily related to CCP's Hong Kong regime as follows.



The cocktail reception was attended by:

- Julia Leung, Deputy Chief Executive Officer and Executive Director, Intermediaries of the Securities and Futures Commission of Hong Kong (centre);
- Louisa Cheang, Vice-Chairman and Chief Executive of Hang Seng Bank (5th from right);
- Rosita Lee, Director and Chief Executive Officer of Hang Seng Investment Management Limited (5th from left);
- Christina Choi, Executive Director, Investment Products of the Securities and Futures Commission of Hong Kong (4th from left);
- Alice Law, Deputy Chairman and Managing Director of the Mandatory Provident Fund Schemes Authority (4th from right); and
- Cheng Yan-chee, Chief Corporate Affairs Officer and Executive Director of the Mandatory Provident Fund Schemes Authority (3rd from right)



(Picture source: Hangsen Bank<sup>11</sup>)

Meng Mei, an independent director since March 2012, founded TusPark—a science park established by Tsinghua University in 1994 to incubate high growth companies—was the director of TusPark’s development center since its inception, also the Chairman of TusHoldings Co., Ltd. and a member of the judging expert panel of China’s National Science & Technology Award. As revealed by European Guanxi, the science parks of PRC were closely related to CCP regime.<sup>12</sup>

Shan Fu, an independent director since July 2018, was appointed as a director by the PIPE Investors in connection with the PIPE transaction described above. Prior to joining Vivo in 2013, Mr. Fu was Senior Managing Director in the Private Equity group and the Chief Representative of Blackstone’s Beijing Office and his experience included serving in the Department of Foreign Investment in CCP’s National Development and Reform Commission, the State Economic and Trade Commission, the Office of Economic and Trade in State Council, and the Office of Production in State Council. It could be evidence at the official website of Vivo Capital.<sup>13</sup>

Qiang Gao, vice president since April 2016, joined Sinovac Beijing in 2002 and had been a quality control manager, quality assurance manager, R&D manager and R&D director at Sinovac Beijing in the past years, and the general manager of Sinovac LS since 2010. Mr. Gao was a member of the Beijing Virus Society, Master of Engineering Supervisor of Institute of Microbiology (CCP's Chinese Academy of Sciences), and a subject review expert of the Beijing Municipal Science and Technology Commission.

It could be easily inferred from the points mentioned above that Sinovac vaccine was a de facto cashing tool of CCP gangsters in collusion with those foreign capitals in Antigua, Hong Kong and USA. Because CCP reigned China simultaneously, it shouldn't be expected that Sinovac vaccine had been scrutinized thoroughly and independently before authorizing for large scale production. Wuhan Institute of Virology was controlled by CCP and it could be inferred here that CCP virus, as unrestricted bioweapon to collapse society and coerce society, was released to sell Sinovac vaccine to obtain criminal proceeds both from Chinese and global consumers via vaccine passport scheme.

The most effective vaccine is to take down Chinese Communist party. Before taking down CCP, any other vaccine is to make vaccine supply chain investors wealthier, make the deceased from toxic vaccine to incur inheritance tax ahead of time on estate being transferred to a descendant and relieve state pension crises.

(The content of the article represents the author's personal opinion)

---

<sup>1</sup> Sinovac LS is a subsidiary of Sinovac.

<https://www.businesswire.com/news/home/20201206005056/en/Sinovac-Secures-Approximately-500-Million-in-Funding-for-COVID-19-Vaccine-Development>

<sup>2</sup> Sinovac's self-introduction. <http://www.sinovac.com.cn/?optionid=451>

<sup>3</sup> Sinovac LS.

<http://qyxy.scjgj.beijing.gov.cn/detail?id=4F88B12F24B43FD96C0E4FB75C96ED83&dataId=a1a1a1a0212deed101212e8b8d2d603e&subMenuCode=01E01E0201%2301E01E0202%2301E01E0203%23&entid=4F88B12F24B43FD96C0E4FB75C96ED83&cid=a1a1a1a0212deed101212e8b8d2d603e&ancheyear=01E01E0201%2301E01E0202%2301E01E0203%23&entType=6180>

<sup>4</sup> Prime Success, L.P. [https://www.sec.gov/Archives/edgar/data/1650757/000090445418000467/s13g\\_070918-sinovac.htm](https://www.sec.gov/Archives/edgar/data/1650757/000090445418000467/s13g_070918-sinovac.htm)

<sup>5</sup> Vivo Capital. <https://sec.report/CIK/0001750117>

<sup>6</sup> Theresa Tse with Sinovac. <https://www.bloomberg.com/press-releases/2020-12-07/sino-biopharm-invests-in-sinovac-ls-a-leading-covid-19-vaccine>

<sup>7</sup> Chairman Theresa Tse.

<https://www1.hkexnews.hk/listedco/listconews/sehk/2019/0429/ltm201904291711.pdf>

<sup>8</sup> Non-transparent Antigua. <https://abipco.gov.ag/efile/#/ocrs/search/SINOVAC%20BIOTECH%20LTD/0>

<sup>9</sup> Annual report. [https://www.sec.gov/Archives/edgar/data/0001084201/000156459020020204/sva-20f\\_20191231.htm](https://www.sec.gov/Archives/edgar/data/0001084201/000156459020020204/sva-20f_20191231.htm)

<sup>10</sup> Charter obeying CCP. <http://www.zlca.org/xhzc>

<sup>11</sup> The Relation between CCP HK and Hangsen Investment.

<https://www.hangseng.com/cms/ccd/schi/PDF/100718s.pdf>

<sup>12</sup> Science park in China. <https://www.europeanguanxi.com/post/science-parks-and-their-role-in-china-s-economy>

<sup>13</sup> History of Shan Fu. <http://vivocapital.com/Team/shan-fu/>